{"version":"1.0","provider_name":"Department of Medicine","provider_url":"https:\/\/www.med.unc.edu\/medicine","author_name":"jake2","author_url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/jake2\/","title":"Dr. Patrick Nachman &amp; Treating ANCA Vasculitis with Rituximab | Department of Medicine","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"eSEaUCG7hL\"><a href=\"https:\/\/www.med.unc.edu\/medicine\/news\/chairs-corner\/podcast\/treating-with-rituximab\/\">Dr. Patrick Nachman &amp; Treating ANCA Vasculitis with Rituximab<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.med.unc.edu\/medicine\/news\/chairs-corner\/podcast\/treating-with-rituximab\/embed\/#?secret=eSEaUCG7hL\" width=\"600\" height=\"338\" title=\"&#8220;Dr. Patrick Nachman &amp; Treating ANCA Vasculitis with Rituximab&#8221; &#8212; Department of Medicine\" data-secret=\"eSEaUCG7hL\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/10\/nachman-1.png","thumbnail_width":400,"thumbnail_height":500,"description":"What should patients know about treatment with rituximab for ANCA vasculitis? What do physicians consider when starting a patient on this medication? Dr. Patrick Nachman and Dr. Ron Falk discuss these details in this podcast. Dr. Nachman is the Covington Distinguished Professor of Medicine in the Division of Nephrology and Hypertension at UNC, and he &hellip; Read more"}